Pharma Focus America

Andelyn Biosciences Partners with CIRM's Accelerating Medicines Partnership for Gene Therapy Consortium

Friday, May 24, 2024

Andelyn Biosciences, Inc., a leading Contract Development and Manufacturing Organization (CDMO) specializing in cell and gene therapy, has been selected by the California Institute for Regenerative Medicine (CIRM) Accelerating Medicines Partnership (AMP) Bespoke Gene Therapy Consortium (BGTC) to manufacture adeno-associated vectors (AAV) therapies using its suspension AAV Curator™ Platform.

This partnership aims to advance BGTC's mission of developing platforms and standards to accelerate the creation and delivery of tailored gene therapies for individuals affected by rare diseases. Specifically, Andelyn will optimize and scale the AAV therapy processes for Congenital Hereditary Endothelial Dystrophy – Type 1.

Andelyn, expressed excitement about the collaboration, highlighting their extensive experience in AAV gene therapies and their alignment with CIRM/BGTC's objectives. He emphasized Andelyn's privilege in working with CIRM/BGTC on its inaugural AMP dedicated to rare diseases, utilizing their AAV Curator™ Platform to address significant challenges in gene therapy development.

Therapeutics Development at CIRM, underscored the importance of this collaboration in driving progress in the field and overcoming manufacturing hurdles, potentially leading to breakthroughs in treating rare diseases like Congenital Hereditary Endothelial Dystrophy.

With its robust capabilities in end-to-end development and manufacturing, spanning three facilities in Columbus, Ohio, Andelyn is poised to advance transformative gene therapies for both rare and common diseases.



Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024